Globus Medical’s price target dips by 9.38% at Leerink Swann: 3 things to know

Leerink Swann lowered Globus Medical’s price target by 9.38 percent to $29, according to a Small Cap Wired report.

Advertisement

Here are three things to know:

 

1. Leerink Swann presently has an “outperform” rating on the stock.

 

2. Out of 10 analysts covering Globus Medical, 11 rate it “buy,” one rates it “sell,” while one rates it “hold.”

 

3. The company has a market cap of $2.31 billion.

 

More articles on devices:
6 things to know about Johnson & Johnson’s stock: Is there long-term strength?
Pacira’s 2015 revenue hits $249M: 5 things to know
Fidia Farmaceutici to introduce treatment for OA-related knee pain — 5 things to know

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Advertisement

Next Up in Spinal Tech

Advertisement

Comments are closed.